In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Shares of Intel and Merck are posting strong returns Friday morning, lifting the Dow Jones Industrial Average into positive territory. Supported by world-class markets data from Dow Jones and ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

CENTER POINT, Ala. (WIAT) — Center Point Fire Department is investigating after a vehicle drove into a building Tuesday morning. Lt. Gov. Ainsworth discusses efforts to widen I-65 The business ...

The project is moving forward to replace the Capitol Square shopping center across from the House of Raeford slaughterhouse.